SETDB1 is a new promising target in HCC therapy

Chin Clin Oncol. 2016 Dec;5(6):73. doi: 10.21037/cco.2016.05.04. Epub 2016 Jun 3.

Authors

Carla Cicchini¹, Cecilia Battistelli¹, Marco Tripodi²

Affiliations

¹ Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.
² Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy. tripodi@bce.uniroma1.it.

PMID: 27334461
DOI: 10.21037/cco.2016.05.04

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma, Hepatocellular / genetics*
Carcinoma, Hepatocellular / pathology
Histone-Lysine N-Methyltransferase
Humans
Liver Neoplasms / genetics*
Liver Neoplasms / pathology
Protein Methyltransferases / genetics*

Substances

Protein Methyltransferases
Histone-Lysine N-Methyltransferase
SETDB1 protein, human